Acadian Asset Management
ORMP icon

Acadian Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Acadian Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50K Buy
+15,066
New +$51.1K ﹤0.01% 1855
2023
Q3 		– Sell
-31,736
Closed -$113K – 1785
2023
Q2 		$113K Buy
+31,736
New +$102K ﹤0.01% 1383

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Acadian Asset Management's ORMP Position: Q1 2026 in Review

Acadian Asset Management opened a new position in Oramed Pharmaceuticals (ORMP) in Q1 2026: 15,066 shares worth $50K. The stake represents ﹤0.01% of the portfolio and ranks #1855 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in ORMP as recently as Q2 2023.

Acadian Asset Management first reported a position in ORMP in Q2 2023 and has held it in 2 quarters since. The position peaked at $113K in Q2 2023. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Acadian Asset Management held 15,066 shares of Oramed Pharmaceuticals worth $50K as of Q1 2026.
  • Oramed Pharmaceuticals was a new Acadian Asset Management position in Q1 2026.
  • Oramed Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1855 holding.
  • Acadian Asset Management first reported a position in Oramed Pharmaceuticals in Q2 2023 and has held it in 2 quarters since.
  • Acadian Asset Management's Oramed Pharmaceuticals position peaked at $113K in Q2 2023.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.